Jerry C.
Jerry’s story may be short, but it’s just another example of how powerful removing grains from your diet, and body, can really be. – Dr. Perlmutter.
I have had heartburn/GERD most of my life. I started the Paleo diet in May of this year and immediately removed all grains from my diet.
Within a week all of my heartburn/GERD was gone. I no longer take Nexium. I have lost over 25 pounds, walk 4 miles each day and overall feel better than I have in many years.
Who would have though removing grains from my diet would cure my heartburn/GERD?!
-Jerry C.
The post Jerry C. appeared first on Dr. David Perlmutter...
Source: Renegade Neurologist - A Blog by David Perlmutter, MD, FACN - October 29, 2013 Category: Neurologists Authors: gbadmin Tags: Success GERD Heartburn Nexium Paleo Source Type: blogs
Purple Haze: How the Purple Pill is Fighting Maine on Cheap Canadian Imports
In case you haven't heard, the pharmaceutical industry -- i.e., PhRMA -- is suing Maine, attempting to block a new law that goes into effect today. "The law, the first of its kind, sanctions the direct purchase of mail-order drugs from some foreign pharmacies. It has ignited a court battle with the pharmaceutical industry and set the stage for a broader fight over access to less-costly medication" (see here for the story plus a copy of PhRMA's complaint and Maine's motion to dismiss). PhRMA contends that the practice could expose residents to tainted or counterfeit medication. "It's not a safety issue," Republican Gov. Pau...
Source: Pharma Marketing Blog - October 9, 2013 Category: Pharma Commentators Tags: PurpleZone AstraZeneca Drug Importation Purple Pill counterfeit medicine Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Rise and shine, everyone. The middle of the week is here, which is, generally, a busy time. Our morning, in fact, got off to an usually interesting start thanks to National Public Radio and WNYC, a local affiliate, which called us to discuss the Merck reorganization (you can listen here). We do this sort of thing, now and again, in case you were not aware. We are also available for conferences, bar mitzvahs and satires. While you ponder the possibilities, here are some tidbits to start the day. Hope you have a smashing time at work and do stay in touch...
J&J Says Dispute With Boehringer May Cause Doxil Shortage (Bloom...
Source: Pharmalot - October 2, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Greetings, everyone. How are you today? A warm sun and crisp breeze are enveloping the Pharmalot corporate campus this morning, where the official mascots are chasing bunnies and the short people are hustling off to their schoolhouses. Busy, busy. And so are we. This calls, of course, for our mandatory cup of stimulation. After all, it is still early in the week. Without some stimulation, we may not make it through the next few days. Perhaps you relate. In any event, here are the tidbits. Have a productive day and keep us in mind when something interesting comes up...
Aesica Pharma Is Fined After Worker Is Sprayed With Che...
Source: Pharmalot - September 24, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and welcome to another working week. Yes, the weekend has come and gone, although we hope you had a chance to relax and refresh yourselves, because that familiar routine of meetings and deadlines and what-not has resumed. This calls, of course, for a cup or two of needed stimulation and, as always, we invite you to join us. Our flavor today is Pumpkin Spice. Meanwhile, here is the usual menu of tidbits to get you going. We hope you have a grand day and drop us a line if you hear something interesting...
FDA Grants Breakthrough Status To Glaxo And Genmab Leukemia Drug (Pharma Times)
Merck Settles False Viox...
Source: Pharmalot - September 16, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Just When You Thought Meta Tags Were Safe, Along Comes Twitter's "Ad Card"
You might recall this post I made three years ago: "Who's in Charge of Your 'Invisible' Metadata? WARNING: Don't Invoke the 'Invisibility Rule'".In that post I pointed out that Google automatically grabs meta data or "tags" (invisible text that describes the content of the web page) from Rx product web sites when generating the content for natural search results. Meta data text is written by the web developer, but it is visible to the Google search engine, which republishes it verbatim as if it owns the content without getting permission from the web developer.If you are an unscrupulous pharma marketer, you can use this to...
Source: Pharma Marketing Blog - September 10, 2013 Category: Pharma Commentators Tags: AstraZeneca social media meta data Source Type: blogs
AZPurpleZone: A Nexium Branded YouTube Channel. "Unusual" for Pharma? Yes. "Engaging Social Media?" No!
"AstraZeneca believes that it is important to share information with patients by engaging with them online," says Ken Graham, Commercial Business Leader, GI, AstraZeneca, in a post to AZ Health Connections Blog (here). "To that end, AstraZeneca recently launched a NEXIUM YouTube channel." It's called "AZPurpleZone."According to AZ's own "white paper" on social media (see attachment to this post), social media is the "catch-all term for internet activities that engage or encourage engagement through online discussions or interactions. While static websites are often the first 'online step' for many companies (e.g., homepage...
Source: Pharma Marketing Blog - July 17, 2013 Category: Pharma Commentators Tags: YouTube AstraZeneca social media Nexium Source Type: blogs
How Much? 'Evergreening' And Drug Costs In One Swiss Town
For several years, the practice of evergreening has been a contentious topic. The term refers to patent extensions that are based on minor changes in a drug and are often employed when a patent is about to expire and modifications are used to claim a newer version of a drug has been hatched. This can allow a drugmaker to seek extended patent protection and keep the cash register ringing.
The practice has prompted complaints that drugmakers exploit the strategy simply to charge higher prices for so-called follow-on drugs that offer little added benefit. South Africa, for instance, wants to change its patent laws to make the...
Source: Pharmalot - June 6, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Another Blow To AstraZeneca: S&P Lowers Its Outlook
Three weeks ago, Pascal Soirot unveiled a months-long effort to rebuild AstraZeneca, which he joined last fall as ceo amid a disheartening lack of new drugs and increased generic competition. His plan revolves around consolidating R&D and global marketing operations over the next two years, a move that will eventually eliminate 1,600 jobs by 2016 and save some $900 million annually. Earlier this year, Soirot also booted the former head of global commercial activities and created a new position to bridge R&D and sales (read more here).
Initially, the response to his plan was enthusiastic, at least among investors. ...
Source: Pharmalot - April 9, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Shire to Forest on Deal List for AstraZeneca: Real M&A - Bloomberg
For AstraZeneca Plc to reverse its worst profit slide, the drugmaker needs to make its biggest purchase since at least 2007. AstraZeneca reported a 37 percent drop in 2012 earnings and forecast profit this year will decline “significantly more than revenue” after the $59 billion company suffered setbacks in developing new therapies to replace best-selling drugs that are losing patent protection. While Chief Executive Officer Pascal Soriot said he will focus on internal efforts and purchases of $3 billion to $4 billion to help boost the lowest valuations in the industry, Exane BNP Paribas said only a “transformationa...
Source: PharmaGossip - February 12, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Pascal Soriot rings the changes in AZ
AstraZeneca in new management shake-up
Both Martin Mackay, president of research and development, and Tony Zook, global commercial executive vice president, have had their roles "eliminated" and are to leave the company at the end of January.
Under a significant management restructure, Mr Soriot has also promoted three members of research and development staff, responsible for drug discovery and development from early to late stages, to his senior executive team, in a sign that the company sees organic drug making as crucial to its future success.
There will also be another three roles at senior executive level represe...
Source: PharmaGossip - January 15, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
How Pharmaceutical Companies Fool Consumers with Me-Too Drugs
I recently listed to an excellent podcast interview of Dr. Marcia Angell by Russ Roberts on Econtalk about the pharmaceutical industry. She is a former editor of the New England Journal and a pathologist by training (see: Angell on Big Pharma). In the interview, she makes a strong case that these companies are not particularly innovative and often quite unscrupulous in their marketing practices. She is a long-time critic of the industry. To support her claim, she discusses "Me-Too" drugs. Here's an excerpt from another article that makes the same points as Dr. Angell (see: Sometimes they're just the...
Source: Lab Soft News - January 7, 2013 Category: Pathologists Authors: Bruce Friedman Tags: Healthcare Business Medical Ethics Pharmaceutical Industry Source Type: blogs
